ENTA Healthcare

Enanta Pharmaceuticals, Inc.

$10.37-0.58%

Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 302.0M USD
Enterprise value: 294.6M USD
Full-time employees: 120

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 0.96 vs a peer median of 0.63), though less than the overall market and more debt relative to equity (1.80× vs a peer median of 0.22×)higher risk: bigger price swings (beta 0.96 vs peers 0.63) and more debt vs equity (1.80× vs peers 0.22×)

Ranks #1,126 of 1,157 healthcare companies (bottom 3%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 40% from September 2022 to August 2026.
Enanta Pharmaceuticals had 40% more shares at August 2026 than at September 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Enanta Pharmaceuticals had 40% more shares at August 2026 than at September 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 28% of revenue in FY Sep 2025.
Enanta Pharmaceuticals paid employees $19M in stock in FY Sep 2025, 28% of its $65M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Investment surge. Capital spending 20% of revenue, up from 2.5% in FY Sep 2022.
Enanta Pharmaceuticals is spending 20% of revenue on facilities and equipment, up from 2.5% in FY Sep 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.
Annual revenue fell three years running. Fiscal-year revenue down each year from FY Sep 2022 to FY Sep 2025.
Enanta Pharmaceuticals's fiscal-year revenue declined in each of the three years to FY Sep 2025.

StockQuotient Score

17/ 100

Oct 5 17 → Nov 4 17

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-20.9%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-18.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-12.2%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield33.5%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

31/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 5.7%

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-6.8%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -1.50Sector median: 0.0584 · MAD: 0.0840

Revenue growth0.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.55Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

16/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 2.7 points to -90.0%

Why

Weaker than most peers on:

▼ ROIC
▼ Operating margin
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-90.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -7.97Sector median: 0.0706 · MAD: 0.1217

Return on assets-21.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.28Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-68.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -7.30Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin100.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-62.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.96

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.00Sector median: 0.6250 · MAD: 0.3380

Current ratio3.76×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.85Sector median: 2.5860 · MAD: 1.3850

Debt / equity1.80×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score -7.75Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Enanta Pharmaceuticals

Is Enanta Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 12, 2026) got weaker in some ways: operating margin fell 2.7 points to -90.0%; 12-month revenue fell 5.7%. Its overall score is unchanged at 17/100 since Oct 28, 2026.
How is Enanta Pharmaceuticals valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -20.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -20.9% vs peers 1.5% (weaker than 100% of peers).
Is Enanta Pharmaceuticals growing?: More slowly than most of its peers. Growth scores 31/100 against 1,393 healthcare peers. 3-year revenue growth -6.8% vs a peer median of 5.8% (weaker than 84% of peers).3-year revenue growth -6.8% vs peers 5.8% (weaker than 84% of peers).
How profitable is Enanta Pharmaceuticals?: Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Return on invested capital -68.6% vs a peer median of 4.7% (weaker than 90% of peers).Return on invested capital -68.6% vs peers 4.7% (weaker than 90% of peers).
How risky is Enanta Pharmaceuticals?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.76× vs a peer median of 2.59× (stronger than 64% of peers).Current ratio 3.76× vs peers 2.59× (stronger than 64% of peers). Debt / equity 1.80× vs a peer median of 0.22× (weaker than 88% of peers).Debt / equity 1.80× vs peers 0.22× (weaker than 88% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 12, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Operating margin fell 2.7 points to -90.0%
12-month revenue fell 5.7%

Worth watching: Enanta Pharmaceuticals is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	69.2M USD	65.3M USD	−5.7%
Net income (12 months)	−62.0M USD	−63.2M USD	+2.0%
Operating margin	-87.2%	-90.0%	−2.7 pts
Free cash flow (12 months)	−9.6M USD	−36.9M USD	+284.4%
Cash	34.9M USD	33.4M USD	−4.3%
Shares outstanding	29.1M	29.1M	+0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Sep 2021	FY Sep 2022	FY Sep 2023	FY Sep 2024	FY Sep 2025	Change
Operating margin	-112.9%	-143.7%	-173.2%	-179.9%	-130.7%	▲ 49 pts
Net margin	-81.4%	-141.3%	-169.0%	-171.6%	-125.4%	▲ 46 pts
Return on assets (ROA)	-18.0%	-32.4%	-28.9%	-30.8%	-29.2%	▲ 1.6 pts
Return on equity (ROE)	-19.8%	-37.9%	-61.7%	-90.1%	-126.5%	▼ 36 pts
Free cash flow margin	-72.9%	-100.9%	-141.7%	-143.0%	-49.2%	▲ 94 pts
Current ratio	8.82×	10.45×	6.73×	5.21×	4.21×	▼ 19%
Interest coverage	—	—	-26.65×	-11.12×	-11.11×	▲ 0.1%

ENTA price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 0.96 vs a peer median of 0.63), though less than the overall market and more debt relative to equity (1.80× vs a peer median of 0.22×)higher risk: bigger price swings (beta 0.96 vs peers 0.63) and more debt vs equity (1.80× vs peers 0.22×)

Ranks #1,126 of 1,157 healthcare companies (bottom 3%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 40% from September 2022 to August 2026.

Enanta Pharmaceuticals had 40% more shares at August 2026 than at September 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Enanta Pharmaceuticals had 40% more shares at August 2026 than at September 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 28% of revenue in FY Sep 2025.

Enanta Pharmaceuticals paid employees $19M in stock in FY Sep 2025, 28% of its $65M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Investment surge. Capital spending 20% of revenue, up from 2.5% in FY Sep 2022.

Enanta Pharmaceuticals is spending 20% of revenue on facilities and equipment, up from 2.5% in FY Sep 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Annual revenue fell three years running. Fiscal-year revenue down each year from FY Sep 2022 to FY Sep 2025.

Enanta Pharmaceuticals's fiscal-year revenue declined in each of the three years to FY Sep 2025.

Questions investors ask about Enanta Pharmaceuticals

Is Enanta Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 12, 2026) got weaker in some ways: operating margin fell 2.7 points to -90.0%; 12-month revenue fell 5.7%. Its overall score is unchanged at 17/100 since Oct 28, 2026.

How is Enanta Pharmaceuticals valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -20.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -20.9% vs peers 1.5% (weaker than 100% of peers).

Is Enanta Pharmaceuticals growing?

More slowly than most of its peers. Growth scores 31/100 against 1,393 healthcare peers. 3-year revenue growth -6.8% vs a peer median of 5.8% (weaker than 84% of peers).3-year revenue growth -6.8% vs peers 5.8% (weaker than 84% of peers).

How profitable is Enanta Pharmaceuticals?

Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Return on invested capital -68.6% vs a peer median of 4.7% (weaker than 90% of peers).Return on invested capital -68.6% vs peers 4.7% (weaker than 90% of peers).

How risky is Enanta Pharmaceuticals?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.76× vs a peer median of 2.59× (stronger than 64% of peers).Current ratio 3.76× vs peers 2.59× (stronger than 64% of peers). Debt / equity 1.80× vs a peer median of 0.22× (weaker than 88% of peers).Debt / equity 1.80× vs peers 0.22× (weaker than 88% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

69.2M USD

65.3M USD

−5.7%

Net income (12 months)

−62.0M USD

−63.2M USD

+2.0%

Operating margin

-87.2%

-90.0%

−2.7 pts

Free cash flow (12 months)

−9.6M USD

−36.9M USD

+284.4%

Cash

34.9M USD

33.4M USD

−4.3%

Shares outstanding

29.1M

29.1M

+0.2%

Key ratios

FY Sep 2021

FY Sep 2022

FY Sep 2023

FY Sep 2024

FY Sep 2025

Change

Operating margin

-112.9%

-143.7%

-173.2%

-179.9%

-130.7%

▲ 49 pts

Net margin

-81.4%

-141.3%

-169.0%

-171.6%

-125.4%

▲ 46 pts

Return on assets (ROA)

-18.0%

-32.4%

-28.9%

-30.8%

-29.2%

▲ 1.6 pts

Return on equity (ROE)

-19.8%

-37.9%

-61.7%

-90.1%

-126.5%

▼ 36 pts

Free cash flow margin

-72.9%

-100.9%

-141.7%

-143.0%

-49.2%

▲ 94 pts

Current ratio

8.82×

10.45×

6.73×

5.21×

4.21×

▼ 19%

Interest coverage

—

-26.65×

-11.12×

-11.11×

▲ 0.1%